Drug notes:
SNT-20109 RD oncology; SNT-101 RD oncology; SNT-3012 RD pancreatic & colorectal cancers
About:
Sonata Therapeutics is developing drugs to reprogram the cellular microenvironment to treat disease. The cellular microenvironment - consisting of signaling molecules such as inflammatory and growth factors - plays an important role in human biology and disease. However, the network of inputs, constituents and targets of the microenvironment have not been fully understood. Sonata is performing a systematic, comprehensive characterization of the cellular microenvironment using pharmacologic and genetic perturbations in diseases of high unmet clinical need. This information feeds into their product-platform to identify new targets for therapeutics. Sonata is generating both small molecule drugs and genetic therapeutics that trigger a diversity of signals to re-engineer the cellular microenvironment.